<DOC>
	<DOCNO>NCT00154726</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , response rate , time treatment failure , overall survival , toxicities Paclitaxel-HDFL regimen locally advanced/inoperable recurrent/metastatic gastric cancer . To evaluate resectability relapse pattern potentially curative resection neoadjuvant Paclitaxel-HDFL regimen</brief_summary>
	<brief_title>Paclitaxel-HDFL Locally Advanced Recurrent/Metastatic Gastric Cancers</brief_title>
	<detailed_description>In treatment metastatic breast cancer , paclitaxel follow weekly HDFL show 55 % response rate anthracycline-resistant patient . Recently , regimen combine paclitaxel moderately-high-dose 5-FU ( 1500mg/m2 ) response rate 61.5 % ( include 23 % CR ) small group gastric cancer patient ( 8 responder 13 patient ) . Thus , sequential use weekly paclitaxel follow weekly HDFL regimen may become new generation chemotherapeutic regimen treatment gastric cancer . Further study large group patient test possible schedule administration warrant .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1.Histologically cytologically confirm gastric adenocarcinoma 2.Measurable evaluable disease 3.No previous C/T 4.Age 18 ~ 70 year 5.KPS &gt; =60 % 6.WBC &gt; =4,000 , pltate &gt; =100K , Creatinine &lt; =1.5mg/dl , serum bil &lt; =1x UNL , transaminase &lt; =3.5x ULN 1.CNS metastasis 2.Patients receive concomitant anticancer C/T R/T 3.Patients pregnant expect life expectancy le 3months 4.Symptomatic heart disease , active infection , extensive liver disease liver cirrhosis 5.TG &lt; =70mg/dl 6.Mental status fit clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>Paclitaxel-HDFL , Locally Advanced Recurrent/Metastatic Gastric Cancer</keyword>
</DOC>